Founded in 2019, Engrail Therapeutics, a biopharmaceutical company focused on the acquisition, development and commercialization of patient-centric neuroscience therapeutics, has raised $32 Million in Series A Financing to develop neuroscience therapeutics.
Engrail’s portfolio is led by a sub-type selective GABA A modulator, ENX-101, and the company plans to use the funding to support its clinical development.
Read more about Engrail Therapeutics here.
Image by Gerd Altmann from Pixabay.
